Press Releases

Date	Title	Format
May 27, 2026	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
April 29, 2026	Amarin Reports 2026 First Quarter Financial Results
April 15, 2026	Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
April 8, 2026	American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
March 18, 2026	Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
March 16, 2026	New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
March 2, 2026	Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
February 25, 2026	Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026	This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
February 11, 2026	Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

ALL-NP-00022 1/23

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT names and logos are trademarks of Amarin Pharmaceuticals Ireland Limited. | ALL-NP-00014 1/23

Get in touch

Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:

How to Contact Us Report Adverse Event

This website is intended for global audiences.